As of my last knowledge update in January 2022, ongoing research and clinical trials for mesothelioma continue to explore various aspects of this rare and aggressive cancer. Some areas of focus include:
Investigating the potential of immunotherapy drugs, such as checkpoint inhibitors and CAR-T cell therapy, to enhance the immune system’s ability to recognize and attack mesothelioma cells.
Researchers are exploring drugs that target specific genetic mutations or proteins found in mesothelioma cells. This approach aims to inhibit the growth and spread of cancer cells while minimizing damage to healthy cells.
Studying gene-based treatments that aim to either repair damaged genes or introduce new genetic material to fight mesothelioma.
Multimodal Treatment Approaches
Investigating combinations of surgery, chemotherapy, radiation therapy, and newer therapies to improve overall treatment outcomes.
Identifying and validating biomarkers that could help in early detection, prognosis, and monitoring of mesothelioma progression. Biomarkers could also aid in developing personalized treatment strategies.
Clinical trials play a crucial role in advancing mesothelioma research by testing new treatments, drug combinations, and innovative therapies. These trials help determine safety, effectiveness, and potential side effects of new approaches in real patient populations.
For the most current information on ongoing mesothelioma research and clinical trials, I highly recommend consulting resources such as the National Cancer Institute (NCI), ClinicalTrials.gov, mesothelioma research centers, and oncology hospitals. Additionally, speaking with healthcare providers who specialize in mesothelioma can provide insights into available clinical trials and their eligibility criteria.